Expression and significance of interleukin-17 in cervical cancer

Shiyu Chen; Yi Quan; Xi Zeng

doi:10.3877/cma.j.issn.1673-5250.2015.04.012

Expression and significance of interleukin-17 in cervical cancer

Shiyu Chen, Yi Quan, Xi Zeng

In: Chung-Hua Fu Ch'an K'o Tsa Chih · 2015 · vol. 11(4) , pp. 492–496 · doi:10.3877/cma.j.issn.1673-5250.2015.04.012 · W3030673879

article OA: closed CC0

Full text JSON View on OpenAlex View at publisher

⚙ AI-generated summary by qwen3.7-flash, 2026-08-29 ⓘ

This study evaluated interleukin-17 expression in cervical cancer tissues compared to benign uterine disease controls, finding significantly higher rates associated with tumor stage and intravascular emboli.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-27 · read from full text ⓘ

This study investigated the expression of interleukin-17 in cervical squamous cell carcinoma tissues compared to normal cervical controls. Researchers analyzed 61 cancer specimens and 9 benign uterine disease samples using immunohistochemistry, finding that IL-17 was significantly more prevalent in cancerous tissue. The results indicated that higher IL-17 expression correlated with advanced FIGO stage and the presence of intravascular cancer emboli, suggesting a link to tumor progression and metastasis. Relevance to endometriosis: adenomyosis is mentioned only as part of the benign control group for comparison; the paper's main focus is cervical cancer.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Objective To evaluate the expression of interleukin (IL)-17 in cervical cancer and analyze the association between the expression of IL-17 and its different clinical characteristics. Methods From January 2011 to January 2013, a total of 61 samples of cervical cancer (cervical squamous cell carcinoma) tissuse were enrolled into study group. At the same time, another 9 case of samples from benign uterine disease (uterine fibroids, adenomyosis) were enrolled into control group. Expression levels of IL-17 in the 9 cases paraffin sections of normal cervical tissues and 61 cases paraffin sections of cervical cancer were detected by streptavidin-biotin complex immunohistochemistry (SABC-IHC). The relationship between the IL-17 expression and its different clinical characteristics were analyzed by statistical method. Results ①IL-17 expressed mainly in the cytoplasm of cervical cancer cells. ②The positive rate of IL-17 expression in study group was 54.1%. The difference of positive rate of IL-17 expression in two groups was significant (χ2=7.17, P<0.01). ③The positive rate of IL-17 expression was significantly higher in patients with peritumor intravascular cancer emboli (66.7%) than those without peritumor intravascular cancer emboli (39.3%), and the difference was significantly different (χ2=4.57, P=0.05); the positive rate of IL-17 expression in patients with International Federation of Gynecology and Obstetrics (FIGO) stage Ⅱ was significantly higher than those with FIGO stage Ⅰ, and the difference was significantly different (χ2=5.59, P=0.05). Conclusions The expression of IL-17 was associated with the development, infiltration and metastasis of cervical cancer. IL-17 may be an important factor for clinical diagnosis and prognosis of cervical cancer. Key words: Interleukin-17; Immunohistochemistry; Uterine cervical neoplasms

Full text 4,633 characters · extracted from oa-doi-fallback · 4 sections · click to expand

Objective

To evaluate the expression of interleukin (IL)-17 in cervical cancer and analyze the association between the expression of IL-17 and its different clinical characteristics.

Methods

From January 2011 to January 2013, a total of 61 samples of cervical cancer (cervical squamous cell carcinoma) tissuse were enrolled into study group. At the same time, another 9 case of samples from benign uterine disease (uterine fibroids, adenomyosis) were enrolled into control group. Expression levels of IL-17 in the 9 cases paraffin sections of normal cervical tissues and 61 cases paraffin sections of cervical cancer were detected by streptavidin-biotin complex immunohistochemistry (SABC-IHC). The relationship between the IL-17 expression and its different clinical characteristics were analyzed by statistical method.

Results

①IL-17 expressed mainly in the cytoplasm of cervical cancer cells. ②The positive rate of IL-17 expression in study group was 54.1%. The difference of positive rate of IL-17 expression in two groups was significant (χ2=7.17, P<0.01). ③The positive rate of IL-17 expression was significantly higher in patients with peritumor intravascular cancer emboli (66.7%) than those without peritumor intravascular cancer emboli (39.3%), and the difference was significantly different (χ2=4.57, P=0.05); the positive rate of IL-17 expression in patients with International Federation of Gynecology and Obstetrics (FIGO) stage Ⅱ was significantly higher than those with FIGO stage Ⅰ, and the difference was significantly different (χ2=5.59, P=0.05).

Conclusions

The expression of IL-17 was associated with the development, infiltration and metastasis of cervical cancer. IL-17 may be an important factor for clinical diagnosis and prognosis of cervical cancer. | [10] | | | [11] | | | [12] | | | [13] | | | [14] | | | [15] | | | [16] | | | [17] | | | [18] | | | [19] | | | [20] | | | [21] | | | [22] | | | [23] | | | [24] | | | [25] | | | [1] | | | [2] | | | [3] | | | [4] | | | [5] | | | [6] | | | [7] | | | [8] | | | [9] | | | [26] | | | [27] | | | [1] | 赵阳, 肖迎聪, 巨艳, 党晓智, 蔡林利, 薛文欣, 李洋, 肖瑶, 郭妤绮, 宋宏萍. 自动乳腺超声联合免疫组化早期预测乳腺癌新辅助化疗病理完全缓解的临床价值[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(04): 361-369. | | [2] | 武壮壮, 张晓娟, 史泽洪, 史瑶, 原韶玲. 超声联合乳腺X线摄影及PR、Her-2预测高级别与中低级别乳腺导管原位癌的价值[J/OL]. 中华医学超声杂志（电子版）, 2023, 20(06): 631-635. | | [3] | 石皆春, 范子玉, 邢燕. 不同筛查方法预警宫颈原位腺癌的效能[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 575-581. | | [4] | 高伟聪, 李丽, 张中华, 朱向辉, 刘素巧. 宫颈癌患者糖调节受损对改良根治术后2年内复发的影响作用[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(02): 231-237. | | [5] | 贺媛媛, 李佳, 杨红. 宫颈中肾腺癌1例并文献复习[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(01): 97-104. | | [6] | 武渊, 朱必清, 何丹, 王海蓉, 李倩. 采取调强放疗联合后装治疗宫颈癌患者的预后模型及危险分层系统构建[J/OL]. 中华妇幼临床医学杂志(电子版), 2023, 19(06): 734-744. | | [7] | 马敏榕, 李聪, 周勤. 宫颈癌治疗研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 497-504. | | [8] | 韩春颖, 王婷婷, 李艳艳, 朴金霞. 子宫内膜癌患者淋巴管间隙浸润预测因素研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 403-409. | | [9] | 陈怡芳, 黄晓卉. 肝细胞癌中对氧磷酶2的表达及临床意义[J/OL]. 中华普通外科学文献(电子版), 2024, 18(03): 186-191. | | [10] | 刘政宏, 王凤力, 吉亚君, 高佳. 胃癌中ELK3蛋白的表达与临床病理特征和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(02): 155-159. | | [11] | 张萌, 喻中华. 阿尔茨海默病患者血清脂联素、Lp-PLA2、IL-17的表达及与认知功能的相关性分析[J/OL]. 中华脑科疾病与康复杂志(电子版), 2023, 13(06): 358-363. | | [12] | 谭瑞义. 小细胞骨肉瘤诊断及治疗研究现状与进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 781-784. | | [13] | 岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J/OL]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770. | | [14] | 黎璞, 生秀杰. 妊娠合并子宫颈癌的管理[J/OL]. 中华产科急救电子杂志, 2024, 13(04): 202-208. | | [15] | 毛高才, 张建波, 袁一方, 毛小波, 戴慧勇, 王哲. 耳后淋巴结内涎腺透明细胞型嗜酸性腺瘤的诊断学特征[J/OL]. 中华诊断学电子杂志, 2023, 11(04): 261-265. | | 阅读次数 | ||||| | 全文 | | |||| | 摘要 | | |||| 版权所有中华医学会中华医学电子音像出版社有限责任公司京ICP备14006079号-1 网络出版服务许可证：(署)网出证(京)字第075号 AI 小编 AI小编

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

adenomyosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex: last seen: 2026-06-04T00:00:01.174412+00:00

License: CC0 · commercial use OK